In stable MS patients, stopping Ocrevus does not seem to increase the risk of disease activity or disability progression for ...
– 75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study – ...
Roche’s subcutaneous version of its multiple sclerosis (MS) med Ocrevus triumphed in a key late-stage study, likely setting up a new opportunity for the blockbuster drug. The study, called OCARINA II, ...
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A study evaluated 182 Black and Hispanic individuals ...
– 35% reduction in risk of needing a walking aid in relapsing multiple sclerosis (RMS) after 7.5 years vs. initiation 2 years later in Phase III open-label extension (OLE) – – 29% reduction in 48-week ...
Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF) multiple sclerosis (MS) drug Ocrevus showed that after 10 years of treatment 77% of patients with relapsing MS were free from disability progression ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus ® (ocrelizumab) and the investigational Bruton’s ...
It may be half a decade since Genentech scored an FDA approval for its multiple sclerosis (MS) drug Ocrevus, but the Roche unit believes it still has a way to go to ensure the central nervous system ...
One-year data continued to support a more convenient, injectable version of Roche’s blockbuster multiple sclerosis (MS) drug Ocrevus ahead of an FDA decision, the Swiss pharma said. A subcutaneous ...
Genentech is "bucking a trend" by charging less for its multiple sclerosis (MS) drug despite at least equal efficacy to others and improved safety, neurologist Michael Racke told BioWorld Today, ...
– 75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results